Mar25Fri

Irish colleges and companies secure €251m of EU science funding

Government targets €1.25bn of total €75bn Horizon 2020 budget

Nearly 600 science projects run through colleges and companies in Ireland won have won funding worth €251 million from the Horizon 2020 programme, the Minister for Skills, Research & Innovation, Damien English, has announced.

Horizon 2020 is the European Union’s programme for Research and Innovation, and it has granted €157 million of that funding to projects in the higher education system and €72 million to companies based in Ireland, English said.

To read the entire article, please click HERE.

Mar17Thu

St. Patrick’s Day Address 2016 – President Michael D. Higgins

May I send my very best wishes for St Patrick’s Day to the people of Ireland and to our global family and friends around the world.  I do so with particular warmth in this year when we commemorate the centenary of one of the most significant events in our nation’s journey to independence – the Easter Rising of 1916.

Read More

Feb09Tue

Member News from ICON Clinical Research

ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases

ICON selected as Data Management Partner for the 100,000 Genomes Project

Dublin, Ireland, 9th February, 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.

A ground-breaking project announced by the British Prime Minister David Cameron in 2012, the100,000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS) cancer and rare disease patients and their families. It aims to demonstrate a new genomic medicine service for the NHS to support better diagnosis and more personalised treatments for patients. De-identified data from the 100,000 Genomes Project will also be made available to approved researchers from industry to help accelerate the development of new treatments and diagnostic tests that are targeted at the genetic characteristics of individual patients.

Read More